New hope for incurable germ cell tumors: cabozantinib trial underway
NCT ID NCT04876456
First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 34 times
Summary
This study tests the drug cabozantinib in 50 adults with germ cell tumors (like testicular or ovarian cancer) that have stopped responding to standard chemotherapy. The goal is to see if the drug can shrink tumors or keep them stable for at least 3 months. Participants take cabozantinib until their disease gets worse or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GERM CELL TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Indiana University Melvin & Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
Conditions
Explore the condition pages connected to this study.